AR038897A1 - Dimeros de avidina eficaces para aumentar la concentracion de biotina radiactiva en la radioinmunoterapia prelocalizada - Google Patents
Dimeros de avidina eficaces para aumentar la concentracion de biotina radiactiva en la radioinmunoterapia prelocalizadaInfo
- Publication number
- AR038897A1 AR038897A1 ARP030100788A ARP030100788A AR038897A1 AR 038897 A1 AR038897 A1 AR 038897A1 AR P030100788 A ARP030100788 A AR P030100788A AR P030100788 A ARP030100788 A AR P030100788A AR 038897 A1 AR038897 A1 AR 038897A1
- Authority
- AR
- Argentina
- Prior art keywords
- avidin
- prelocalized
- dimers
- increase
- diavidins
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
- A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6891—Pre-targeting systems involving an antibody for targeting specific cells
- A61K47/6897—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies
- A61K47/6898—Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies using avidin- or biotin-conjugated antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Nanotechnology (AREA)
- Genetics & Genomics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- General Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Crystallography & Structural Chemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Dímeros de avidina (diavidinas) con diferentes longitudes del conector que, a su vez, está ligado a diferentes grupos funcionales (-NH2 o -COOH) de avidina. En comparación con la avidina, las diavidinas presentan la capacidad para aumentar la cantidad de biotina marcada en el objetivo, cuando se utiliza en una prueba de prelocalización in vitro utilizando tenascina humana soportada, el anticuerpo monoclonal antitenascina biotinilado (Mab-B), avidina/diavidina, y biotina-3H. Empleo de dichas diavidinas en el diagnóstico de cáncer y terapia anticáncer en base al procedimiento de radioinmunoterapia prelocalizada compuesta por tres etapas.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT2002RM000128A ITRM20020128A1 (it) | 2002-03-08 | 2002-03-08 | Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting". |
Publications (1)
Publication Number | Publication Date |
---|---|
AR038897A1 true AR038897A1 (es) | 2005-02-02 |
Family
ID=11456156
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP030100788A AR038897A1 (es) | 2002-03-08 | 2003-03-07 | Dimeros de avidina eficaces para aumentar la concentracion de biotina radiactiva en la radioinmunoterapia prelocalizada |
Country Status (22)
Country | Link |
---|---|
US (2) | US7425317B2 (es) |
EP (1) | EP1482981B1 (es) |
JP (1) | JP4362376B2 (es) |
KR (1) | KR100993626B1 (es) |
CN (1) | CN1638807B (es) |
AR (1) | AR038897A1 (es) |
AT (1) | ATE395937T1 (es) |
AU (1) | AU2003217467B2 (es) |
BR (1) | BR0308117A (es) |
CA (1) | CA2475534C (es) |
CY (1) | CY1108268T1 (es) |
DE (1) | DE60321142D1 (es) |
DK (1) | DK1482981T3 (es) |
ES (1) | ES2302917T3 (es) |
HK (1) | HK1078462A1 (es) |
IT (1) | ITRM20020128A1 (es) |
MX (1) | MXPA04008639A (es) |
PL (1) | PL372721A1 (es) |
PT (1) | PT1482981E (es) |
SI (1) | SI1482981T1 (es) |
TW (1) | TWI345982B (es) |
WO (1) | WO2003075960A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7438908B2 (en) | 2002-02-26 | 2008-10-21 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Anti-human tenascin monoclonal antibody |
ITRM20020128A1 (it) * | 2002-03-08 | 2003-09-08 | Sigma Tau Ind Farmaceuti | Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting". |
ITRM20040105A1 (it) * | 2004-02-27 | 2004-05-27 | Tecnogen Scpa | Anticorpo monoclonale antitenascina umana. |
JP2008064475A (ja) * | 2006-09-04 | 2008-03-21 | Osaka Univ | 標的物質の高感度検出方法、検出用キットおよび検出装置 |
EP2941243A4 (en) | 2013-01-04 | 2016-09-14 | Massachusetts Inst Technology | SURFACE BINDING IN THE ADMINISTRATION OF A MEDICAMENT ON NANOPARTICLE BASE IN A TISSUE |
CN105214843A (zh) * | 2015-10-20 | 2016-01-06 | 东莞市利发爱尔空气净化系统有限公司 | 一种高压放电单元及空气净化器 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4687732A (en) * | 1983-06-10 | 1987-08-18 | Yale University | Visualization polymers and their application to diagnostic medicine |
DE69331319T2 (de) * | 1992-06-09 | 2002-08-08 | Neorx Corp | Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren |
US5482698A (en) * | 1993-04-22 | 1996-01-09 | Immunomedics, Inc. | Detection and therapy of lesions with biotin/avidin polymer conjugates |
ITRM20020128A1 (it) * | 2002-03-08 | 2003-09-08 | Sigma Tau Ind Farmaceuti | Dimeri di avidina efficaci nell'incrementare la concentrazione di biotina radioattiva nella immunoterapia con "pretargeting". |
-
2002
- 2002-03-08 IT IT2002RM000128A patent/ITRM20020128A1/it unknown
-
2003
- 2003-02-27 TW TW092104307A patent/TWI345982B/zh not_active IP Right Cessation
- 2003-03-06 SI SI200331230T patent/SI1482981T1/sl unknown
- 2003-03-06 PT PT03712655T patent/PT1482981E/pt unknown
- 2003-03-06 KR KR1020047013257A patent/KR100993626B1/ko not_active IP Right Cessation
- 2003-03-06 ES ES03712655T patent/ES2302917T3/es not_active Expired - Lifetime
- 2003-03-06 CA CA2475534A patent/CA2475534C/en not_active Expired - Fee Related
- 2003-03-06 DE DE60321142T patent/DE60321142D1/de not_active Expired - Lifetime
- 2003-03-06 EP EP03712655A patent/EP1482981B1/en not_active Expired - Lifetime
- 2003-03-06 MX MXPA04008639A patent/MXPA04008639A/es active IP Right Grant
- 2003-03-06 AT AT03712655T patent/ATE395937T1/de active
- 2003-03-06 AU AU2003217467A patent/AU2003217467B2/en not_active Ceased
- 2003-03-06 CN CN038046369A patent/CN1638807B/zh not_active Expired - Fee Related
- 2003-03-06 DK DK03712655T patent/DK1482981T3/da active
- 2003-03-06 WO PCT/IT2003/000135 patent/WO2003075960A1/en active IP Right Grant
- 2003-03-06 US US10/506,159 patent/US7425317B2/en not_active Expired - Fee Related
- 2003-03-06 PL PL03372721A patent/PL372721A1/xx not_active Application Discontinuation
- 2003-03-06 BR BR0308117-6A patent/BR0308117A/pt not_active IP Right Cessation
- 2003-03-06 JP JP2003574233A patent/JP4362376B2/ja not_active Expired - Fee Related
- 2003-03-07 AR ARP030100788A patent/AR038897A1/es unknown
-
2005
- 2005-11-18 HK HK05110361.5A patent/HK1078462A1/xx not_active IP Right Cessation
-
2008
- 2008-07-03 US US12/216,449 patent/US7807133B2/en not_active Expired - Fee Related
- 2008-08-18 CY CY20081100874T patent/CY1108268T1/el unknown
Also Published As
Publication number | Publication date |
---|---|
AU2003217467A1 (en) | 2003-09-22 |
PT1482981E (pt) | 2008-07-15 |
US20090010839A1 (en) | 2009-01-08 |
WO2003075960A1 (en) | 2003-09-18 |
HK1078462A1 (en) | 2006-03-17 |
KR20040093067A (ko) | 2004-11-04 |
TWI345982B (en) | 2011-08-01 |
EP1482981B1 (en) | 2008-05-21 |
CN1638807B (zh) | 2010-05-26 |
TW200306207A (en) | 2003-11-16 |
KR100993626B1 (ko) | 2010-11-11 |
CN1638807A (zh) | 2005-07-13 |
SI1482981T1 (sl) | 2008-08-31 |
ITRM20020128A0 (it) | 2002-03-08 |
JP2005529081A (ja) | 2005-09-29 |
CY1108268T1 (el) | 2014-02-12 |
US20050106102A1 (en) | 2005-05-19 |
AU2003217467B2 (en) | 2008-06-26 |
MXPA04008639A (es) | 2004-12-06 |
ATE395937T1 (de) | 2008-06-15 |
CA2475534A1 (en) | 2003-09-18 |
DK1482981T3 (da) | 2008-09-01 |
CA2475534C (en) | 2011-06-14 |
PL372721A1 (en) | 2005-07-25 |
EP1482981A1 (en) | 2004-12-08 |
US7425317B2 (en) | 2008-09-16 |
US7807133B2 (en) | 2010-10-05 |
ITRM20020128A1 (it) | 2003-09-08 |
ES2302917T3 (es) | 2008-08-01 |
BR0308117A (pt) | 2005-01-04 |
DE60321142D1 (de) | 2008-07-03 |
JP4362376B2 (ja) | 2009-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1120070T1 (el) | Μεθοδοi θεραπευτικης αγωγης με τη χρηση συζευγματων αντισωματος εναντι-erbb-μεϋτανσινοειδους | |
CY1113247T1 (el) | Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου | |
BR0314038A (pt) | Anticorpo humano isolado, método de tratar uma doença mediada com il-1 em um paciente, composição farmacêutica, cadeias pesada e leve, e, método de mapeamento de epitopo de um antìgeno selecionado | |
CY1123400T1 (el) | Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις | |
AR035977A1 (es) | Inmunoconjugados de anticuerpos cd44 citotoxicos. | |
CR7786A (es) | Anticuerpos neutralizantes contra gdf-8 y el uso de los mismos | |
CY1115212T1 (el) | Διαμεσολαβηση στην κυτταροτοξικοτητα των κυτταρων που παρουσιαζουν eπιφaneiakh εκφραση της cd44 | |
EA200301250A1 (ru) | Фармацевтические композиции, содержащие слаборастворимые и/или чувствительные к кислотам лекарственные средства и нейтрализованные кислотные полимеры | |
CY1109034T1 (el) | Τροποποιημενες κυτοκινες για χρηση σε θεραπεια καρκινου | |
DE602005026789D1 (de) | Le | |
ATE521366T1 (de) | Anwendung von amatoxin-konjugaten und phallotoxin-konjugaten mit makromolekülen zur krebstherapie und therapie von entzündungen | |
CY1108597T1 (el) | Συνθεσεις που περιεχουν παραγοντα συνδεσης υποδοχεα οχ-40 ή νουκλεϊνικο οξυ που κωδικοποιει αυτον και μεθοδοι για αυξηση της αντιγονου-ειδικης ανοσοαποκρισης | |
BRPI0210579B8 (pt) | anticorpo e composição farmacêutica | |
CY1109744T1 (el) | Συζυγη και μεθοδοι για την παραγωγη τους, και η χρηση τους για την μεταφορα μοριων δια μεσου βιολογικων μεμβρανων | |
CY1107018T1 (el) | Τεχνητο ανοσο οργανο | |
CR10143A (es) | Antígenos de ácido des-n-acetil-siálico, anticuerpos para los mismos y métodos de uso en la terapia del cáncer | |
CO5370684A1 (es) | Anticuerpos humanos que se unen a mn y tienen actividad neutralizante de la adhesion celular | |
AR038897A1 (es) | Dimeros de avidina eficaces para aumentar la concentracion de biotina radiactiva en la radioinmunoterapia prelocalizada | |
PE20050962A1 (es) | Anticuerpos completamente humanos contra 4-1bb humano | |
CY1112740T1 (el) | ΧΡΗΣΗ ΔΕΝΔΡΙΤΙΚΩΝ ΚΥΤΤΑΡΩΝ (DCs) ΕΚΦΡΑΖΟΝΤΑΣ ΙΝΤΕΡΛΕΥΚΙΝΗ 12 (IL-12) | |
ATE442861T1 (de) | Gegen antikörper gerichtete photodynamische therapie | |
DK1526840T3 (da) | Nanopartikler til DNA administration til et målorgan | |
DE60113445D1 (de) | Substanzen mit verzweigten linkermolekülen | |
EE05474B1 (et) | Antikehade kasutamine farmatseutilise kompositsiooni valmistamiseks, mis on ette nhtud vhivastaseks vaktsineerimiseks | |
ES2178961B1 (es) | Fabricacion de nanoparticulas a base del copolimero de metil vinil eter y anhidrido maleico para la administracion de farmacos de naturaleza hidrofilica, en particular de bases puricas y pirimidinicas. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |